Selective Cytotoxicity Evaluation in Anticancer Drug Screening of Fractionated Plant Extracts

Monks, 1991, Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines, J Natl Cancer Inst, 83, 757, 10.1093/jnci/83.11.757 Alley, 1988, Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay, Cancer Res, 48, 589 Boyd, 1995, Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen, Drug Dev Res, 34, 91, 10.1002/ddr.430340203 Paull, 1989, Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and compare algorithm, J Natl Cancer Inst, 81, 1088, 10.1093/jnci/81.14.1088 Drug Therapeutics Program web page, 2001. Available at dtp.nci.nih.gov/index Lee, 1999, Novel antitumor agents from higher plants, Antitumor Agents, 197, 569 Dhar, 1996, Anti-cancer drug characterization using a human cell line panel representing defined types of drug resistance, Br J Cancer, 74, 888, 10.1038/bjc.1996.453 Shoemaker, 1985, Application of a human tumor colony-forming assay to new drug screening, Cancer Res, 45, 2145 Fridborg, 1999, Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic, Eur J Cancer, 35, 424, 10.1016/S0959-8049(98)00286-X Dhar, 1998, A nonclonogenic cytotoxicity assay using primary cultures of patient tumor cells for anticancer drug screening, J Biomol Screen, 3, 207, 10.1177/108705719800300307 Claeson, 1998, Fractionation protocol for the isolation of polypeptides from plant biomass, J Nat Prod, 61, 77, 10.1021/np970342r Larsson, 1992, Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA), Int. J Cancer, 50, 177, 10.1002/ijc.2910500204 Csoka, 1994, Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric cytotoxicity assay (FMCA), Gynecol Oncol, 54, 163, 10.1006/gyno.1994.1187 Hudson, 1989, 89 Dhar S, Nygren P, Csoka K, et al: Feasibility of a non-clonogenic cytotoxicity assay of primary human tumor cells for new anticancer drug screening (UI: 98641070). In Proceedings of the Annual Meeting of the American Association for Cancer Research, 1997;38:A4070. Larsson, 1990, Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay: reversal of resistance and selective cytotoxic action of cyclosporin A and verapamil on MDR leukemia T-cells, Int J Cancer, 46, 67, 10.1002/ijc.2910460114 Larsson, 1990, Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay, Leukemia, 4, 567 Johansson, 2001, Cytotoxicity of digitoxin and related cardiac glycosides in human tumour cells, Anti-Cancer Drugs, 12, 475, 10.1097/00001813-200106000-00009 Lindholm, 2002, Cyclotides a novel type of cytotoxic agents, Mol Cancer Ther, 1, 365 Johansson, 2002, A neutrophil multitarget functional bioassay to detect anti-inflammatory natural products, J Nat Prod, 65, 32, 10.1021/np010323o